Literature DB >> 31662546

VEGF Inhibitors Do Not Increase D-dimer Levels in Colorectal Cancer Patients Without Venous Thromboembolism: A Retrospective Non-inferiority Analysis

Hirokazu Toshima1, Toshikazu Ikusue2, Atsushi Hisamatsu2, Kouji Kobayashi2, Hiroo Ishida2, Ken Shimada2.   

Abstract

BACKGROUND/AIM: If VEGF inhibitors contribute to an increase in D-dimer levels, they may adversely affect the diagnosis of venous thromboembolism (VTE). Consequently, this retrospective study examined the effects of VEGF inhibitors on D-dimer levels in colorectal cancer patients. PATIENTS AND METHODS: A total of 104 colorectal cancer patients who received chemotherapy, were included in this study. To perform D-dimer analysis, patients were divided into two analysis targets: patients with VTE and without VTE. Statistical analysis included a natural logarithmic transformation of D-dimer data.
RESULTS: In the D-dimer analysis of non-VTE patients, the natural logarithm D-dimer mean difference was -0.186, with a 95% CI of -0.525 to 0.154. The upper limit of the 95%CI (0.154) did not exceed the non-inferiority margin (Δ) of 0.199, and therefore met the non-inferiority criteria.
CONCLUSION: VEGF inhibitors don't contribute to increased D-dimer levels in colorectal cancer patients without VTE. Copyright
© 2019, International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved.

Entities:  

Keywords:  Pan-Asian adapted ESMO consensus guidelines; Vascular endothelial growth factor inhibitor; chemotherapy; deep vein thrombosis; pulmonary embolism

Mesh:

Substances:

Year:  2019        PMID: 31662546      PMCID: PMC6899133          DOI: 10.21873/invivo.11712

Source DB:  PubMed          Journal:  In Vivo        ISSN: 0258-851X            Impact factor:   2.155


  22 in total

1.  Long-term outcomes of cancer-related isolated distal deep vein thrombosis: the OPTIMEV study.

Authors:  J-P Galanaud; M-A Sevestre; G Pernod; C Genty; S Richelet; S R Kahn; C Boulon; H Terrisse; I Quéré; J-L Bosson
Journal:  J Thromb Haemost       Date:  2017-04-21       Impact factor: 5.824

2.  A model for the harmonisation of test results of different quantitative D-dimer methods.

Authors:  Piet Meijer; Frits Haverkate; Cornelis Kluft; Philippe de Moerloose; Bert Verbruggen; Michael Spannagl
Journal:  Thromb Haemost       Date:  2006-03       Impact factor: 5.249

3.  Pan-Asian adapted ESMO consensus guidelines for the management of patients with metastatic colorectal cancer: a JSMO-ESMO initiative endorsed by CSCO, KACO, MOS, SSO and TOS.

Authors:  T Yoshino; D Arnold; H Taniguchi; G Pentheroudakis; K Yamazaki; R-H Xu; T W Kim; F Ismail; I B Tan; K-H Yeh; A Grothey; S Zhang; J B Ahn; M Y Mastura; D Chong; L-T Chen; S Kopetz; T Eguchi-Nakajima; H Ebi; A Ohtsu; A Cervantes; K Muro; J Tabernero; H Minami; F Ciardiello; J-Y Douillard
Journal:  Ann Oncol       Date:  2018-01-01       Impact factor: 32.976

4.  Antithrombotic Therapy for VTE Disease: CHEST Guideline and Expert Panel Report.

Authors:  Clive Kearon; Elie A Akl; Joseph Ornelas; Allen Blaivas; David Jimenez; Henri Bounameaux; Menno Huisman; Christopher S King; Timothy A Morris; Namita Sood; Scott M Stevens; Janine R E Vintch; Philip Wells; Scott C Woller; Lisa Moores
Journal:  Chest       Date:  2016-01-07       Impact factor: 9.410

Review 5.  D-dimer assays for the exclusion of venous thromboembolism.

Authors:  G Reber; P de Moerloose
Journal:  Semin Thromb Hemost       Date:  2000       Impact factor: 4.180

Review 6.  Does this patient have deep vein thrombosis?

Authors:  Philip S Wells; Carolyn Owen; Steve Doucette; Dean Fergusson; Huyen Tran
Journal:  JAMA       Date:  2006-01-11       Impact factor: 56.272

7.  Hospitalisation for venous thromboembolism in cancer patients and the general population: a population-based cohort study in Denmark, 1997-2006.

Authors:  D P Cronin-Fenton; F Søndergaard; L A Pedersen; J P Fryzek; K Cetin; J Acquavella; J A Baron; H T Sørensen
Journal:  Br J Cancer       Date:  2010-09-14       Impact factor: 7.640

8.  The effect of epsilon-aminocaproic acid and aprotinin on fibrinolysis and blood loss in patients undergoing primary, isolated coronary artery bypass surgery: a randomized, double-blind, placebo-controlled, noninferiority trial.

Authors:  Philip E Greilich; Michael E Jessen; Neeraj Satyanarayana; Charles W Whitten; Gregory A Nuttall; Joseph M Beckham; Michael H Wall; John F Butterworth
Journal:  Anesth Analg       Date:  2009-07       Impact factor: 5.108

Review 9.  Venous thromboembolism and prognosis in cancer.

Authors:  Alok A Khorana
Journal:  Thromb Res       Date:  2010-01-25       Impact factor: 3.944

Review 10.  Mechanisms of adverse effects of anti-VEGF therapy for cancer.

Authors:  T Kamba; D M McDonald
Journal:  Br J Cancer       Date:  2007-05-22       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.